IMP3 and cancer: As shown in Fig. 3, treatment of HCT-116 cells with IMP3 siRNA increased the sensibility of CRC cells to 5-fluoruoracil and oxaliplatin, suggesting that IMP3 knockdown could potentially be deployed as an anti-cancer drug in the combinatorial approaches with chemotherapeutic drugs.